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Objective. To provide a clinically relevant overview of the analytical interference by contrast agents (CA) in laboratory blood test
measurements.Materials andMethods.The effects of five CAs, gadobutrol, gadoterate meglumine, gadoxetate disodium, iodixanol,
and iomeprol, were studied on the 29most frequently performed biochemical assays. One-day-old plasma, serum, and whole blood
were spiked with doses of each agent such that the gadolinium agents and the iodine agents reached concentrations of 0.5mM and
12mg iodine/mL, respectively. Subsequently, 12 assays were reexamined using 1/2 and 1/4 of these CA concentrations. The results
were assessed statistically by a paired Student’s 𝑡-test. Results. Iodixanol produced a negative interference on the bicarbonate (𝑝 =
0.011), lactate dehydrogenase (𝑝 < 0.0001), and zinc (𝑝 = 0.0034) assays and a positive interference on the albumin (𝑝 = 0.0062),
calcium (𝑝 < 0.0001), ionized calcium (𝑝 = 0.0086), iron (𝑝 < 0.0001), and potassium (𝑝 = 0.0003) assays. Iomeprol produced
a negative interference on the bicarbonate (𝑝 = 0.0057) and magnesium (𝑝 = 0.0001) assays and a positive interference on the
calcium (𝑝 < 0.0001) and potassium (𝑝 = 0.0012) assays. Gadoxetate disodium produced a negative interference on the iron
(𝑝 < 0.0001) and zinc (𝑝 < 0.0001) assays and a positive interference on the sodium (𝑝 = 0.032) assay. Conclusion. CAs cause
analytical interference. Attention should be given to the above-mentioned analyte-CA combinations when assessing laboratory
blood test results obtained after CA administration.
1. Introduction
Radiological imaging and laboratory blood tests are used
together to diagnose and treat patients. To optimize the
physician’s evaluation and reduce the inconvenience for the
patient, ideally, all planned examinations and tests should
be performed on one day or within a few days. Due to the
patients’ busy schedules, blood samples may be taken after a
computed tomography (CT) or a magnetic resonance (MR)
examination. To ensure patient safety, results obtained using
patient blood samples must be valid.
The gadolinium-based contrast agents (GdCA) and the
iodine-based contrast agents (ICA) are the contrast agents
(CA) that in their class are among the most frequently used
agents [1]. GdCAs have been reported to interfere with the
determination of calcium [2–13], iron [5, 12, 14, 15], zinc,
copper [5, 11, 16], angiotensin-converting enzyme, creatinine,
bilirubin, protein [5, 12, 13, 17–21] and magnesium [12], and
the ICAs interfere with the copper, iron, phosphate, bilirubin,
and protein assays [5, 19, 22–27].The effects of CAs, especially
ICAs, on laboratory blood tests have not been studied system-
atically; therefore, guidelines are based on CA elimination
instead of assay-specific recommendations [23, 25, 28, 29].
We performed an in vitro study on the analytical interference
caused by contrast agents in laboratory blood tests.
A study was conducted to test the effect of one agent from
each of the most frequently used classes of CAs on the most
frequently performed laboratory blood tests.
2. Materials and Methods
2.1. Contrast Agents. The analytical experiments were per-
formed at the Department of Clinical Biochemistry, Copen-
hagen University Hospital Herlev between February 2 and
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March 17, 2015.The following five commercially available CAs
were selected based on their clinical relevance, that is, among
the most commonly used agents in their class world-wide.
In addition, they represent different properties of GdCAs
and ICAs: a nonionic monomer, low-osmolar ICA, and
iomeprol (Iomeron, Bracco Imaging SpA, Milano, Italy); a
nonionic dimer, iso-osmolar ICA, and iodixanol (Visipaque,
GE Healthcare, Little Chalfont, United Kingdom); an ionic
linear GdCA and gadoxetate disodium (Primovist, Bayer
Healthcare, Berlin, Germany); an ionic macrocyclic GdCA
and gadoterate meglumine (Dotarem, Guerbet, Villepinte,
France); and a nonionic macrocyclic GdCA, gadobutrol
(Gadovist, Bayer Healthcare, Berlin, Germany).
2.2. Preparation of Solutions. Test solutions were prepared by
serial dilutions of the various CAs with saline (0.9%), from
which 40 𝜇L was added to 1mL of pooled plasma and pooled
serum, and 48 𝜇L was added to 1.20mL of whole blood. This
procedure was repeated 14 times with the initial high concen-
tration of the CAs, providing results from 14 different pools.
The haematology assays were repeated 14 times on 14 samples
of whole blood. The final concentration of 0.5mM gadolin-
ium (Gd) and 12mg iodine/mL corresponds to the estimated
peak serum concentration achieved in vivo at a standard dose
[15, 30]. The standard dose is defined as 0.1mmol/kg GdCA
and 120mL of a 300mg iodine/mL ICA [28]. The control
samples were corrected for the dilution using 0.9% saline.
The samples were collected from lithium heparin-treated
blood in a gel separator tube (Vacuette LH LithiumHeparin
Sep, Greiner Bio-One); citrate/citric acid buffer-treated blood
(Vacuette FC Mix, Greiner Bio-One); clot activator-treated
blood in a gel separator tube (Vacuette Z Serum Sep Clot
Activator, Greiner Bio-One); clot activator-treated blood
(Vacuette Z SerumClot Activator, Greiner Bio-One); citrated
plasma (Vacuette 9NC Coagulation Sodium Citrate, Greiner
Bio-One); and K3 EDTA-treated blood (Vacuette K3E
K3EDTA, Greiner Bio-One); and analytes were tested from
the most appropriate tube (Table 1), from which all patient
demographic data were removed [31].
2.3. Analytes and Biochemical Assays. The analysers and bio-
chemical assays that were used are listed in Table 1. Initially,
the 29 biochemical assays were tested on 14 test solutions, one
measurement for each prepared test solution, and 12 assays
were retested with lower CA concentrations based on the first
results. The test solutions were incubated at room tempera-
ture and then analysed after 2–4 h and again after 24 h. All
reagents and assays were obtained from the manufacturer
of the analyser and used according to the manufacturers’
instructions.
The assays that were performed on the Vitros 5.1 Chem-
istry System are dry chemistry methods that use MicroSlides
that contain the necessary reagents in dried form. There are
two types of MicroSlides; the colorimetric/rate (CM/Rate)
and the immunorate (IR) slides measure the analyte activity
or concentration, whereas the potentiometric (PM) slides
measure potassium and sodium by direct potentiometry [32].
The three assays performed in the KonelabTM PRIME
60i Clinical Chemistry Analyzer use wet chemistry methods
[33]. The two analytes C-reactive proteins (CRP) and zinc
are measured by turbidimetric and colorimetric principles,
respectively. Ionized calcium is measured by direct poten-
tiometry using saline with calcium chloride as the calibrator.
The results are reported as concentrations after adjusting the
results to a plasma pH of 7.4 [33].
The coagulation factors II + VII + X assay that was per-
formed on an ACL TOP 700 CTS is a wet chemistry method
that is based on turbidimetric principles and uses Owren’s
prothrombin time (PT) reagents (Medirox AB, Nyko¨ping,
Sweden).
The haematology analytes were assayed on the ADVIA
2120i System with Autoslide using wet chemistry, flow
cytometry, and peroxidase staining methodologies, with the
exception of the haemoglobin assay that uses a standard
cyanmethemoglobin colorimetric method [34].
None of the reagent manufacturers identified contrast
agents as interferents or noninterferents in their assay kit
inserts. Iodide was specified as a noninterferent in the glucose
and creatinine assays, which were performed on the Vitros 5.1
Chemistry System.
The assays that exhibited a clinically relevant change, i.e.,
exceeding the Desirable Analytical Quality Specifications for
bias, in the presence of aCAwere repeated at reduced concen-
trations, 6 and 3mg iodine/mL and 0.25 and 0.125mMGd.
The assays were repeated six times on six different pools.
2.4. Statistical Analysis. A paired Student’s 𝑡-test was used to
assess the statistical significance of the differences observed.
The ANOVA test was used to analyse the two parameter con-
centrations and the type of drug when relevant.The statistical
tests were performed using the statistical computer software
R 3.1.2 for Windows (an open source software initially
written by Robert Gentleman and Ross Ihaka of the Statistics
Department of the University of Auckland) [35]. Desirable
Analytical Quality Specifications for imprecision, bias, and
total error derived from intra- and interindividual biologic
variation were used to assess the clinical relevance of the
statistically significant changes in the analyte concentrations
[36]. The results are shown as percentage change as follows:
Change% = ((𝐶CA−𝐶Control)/𝐶control)∗100, in which aminus
or a plus sign indicates a decrease or increase in the results,
respectively.
3. Results
The results of the assays that exhibited clinically relevant
interference by a contrast agent concentration of 0.5mMGd
and 12mg iodine/mL are presented in Table 2. Only the
results that were obtained after 2–4 h of incubation are pre-
sented. Interference by iodixanol, iomeprol, and gadoxetate
disodium was observed in a total of 10 assays performed on
the Vitros 5.1 FS Chemistry System and KonelabTM PRIME
60i Clinical Chemistry Analyzer.
For some of the assays, the incubation time was a factor,
as clinically relevant changeswere observed after 24 h of incu-
bation but not after 2–4 h of incubation. The assays that were
Contrast Media & Molecular Imaging 3
Table 1: Analysers, biochemical assays, and test tubes (Vacuette Greiner Bio-One).
Analyser Analyte Method (Reagents) Test tubes (Vacuette)
Vitros 5.1 FS Chemistry System,
Ortho-Clinical Diagnostics,
Johnson & Johnson, Birkerød,
Denmark
Alanine amino
transferase
Enzymatic, multiple-point rate
(pyridoxal-5-phosphate) LH Lithium Heparin Sep
Albumin∗ Direct colorimetry (bromocresol green dye) LH Lithium Heparin Sep
Alkaline phosphatase Multiple-point rate (p-nitrophenyl phosphate) LH Lithium Heparin Sep
Aspartate amino
transferase
Enzymatic, multiple-point rate
(pyridoxal-5-phosphate) LH Lithium Heparin Sep
Bicarbonate∗ Enzymatic, end-point (malate dehydrogenase) LH Lithium Heparin Sep
Bilirubin, total∗ Colorimetry (dyphylline, diazonium salt) LH Lithium Heparin Sep
Calcium∗ Direct colorimetry (arsenazo III dye) LH Lithium Heparin Sep
Creatinine Enzymatic, two-point rate (isotope dilution massspectrometry (IDMS) standardized) LH Lithium Heparin Sep
Glucose Enzymatic, colorimetry (glucose oxidase method) FC Mix
Iron∗ Two-point rate (3-pyridine sulphonamide dye) LH Lithium Heparin Sep
Lactate
dehydrogenase∗ Enzymatic, multiple-point rate (sodium pyruvate) LH Lithium Heparin Sep
Magnesium∗ Colorimetry (formazan dye) LH Lithium Heparin Sep
Phosphorus Colorimetry (phosphomolybdate reduction) LH Lithium Heparin Sep
Potassium∗ Direct potentiometry (valinomycin) LH Lithium Heparin Sep
Sodium∗ Direct potentiometry (methyl monensin) LH Lithium Heparin Sep
Urea Colorimetry (urease, ammonia indicator) LH Lithium Heparin Sep
Konelab PRIME 60i Clinical
Chemistry Analyzer, Thermo
Fischer Scientific Inc., ILS
Laboratories Scandinavia ApS,
Allerød, Denmark
C-reactive protein Turbidimetry, measurement of antigen-antibodyprecipitation (polyethylene glycol) Z Serum Sep Clot Activator
Ionized calcium∗ Direct potentiometry (ion selective electrode) Z Serum Sep Clot Activator
Zinc∗ Direct colorimetry (dye 5-Br-PAPS) Z Serum Clot Activator
ACL TOP 700 CTS,
Instrumentation Laboratories,
Lexington, MA, USA.
Coagulation factors II
+ VII + X∗
Turbidimetry (Owren’s prothrombin time (PT)
reagents)
9NC Coagulation Sodium
Citrate
ADVIA 2120i System with
Autoslide, Siemens Healthcare
Diagnostics, Ballerup, Denmark
Basophilocytes
The haematology assays included flow cytometry
and leucocyte differential counting using a
peroxidase staining methodology.
Hemoglobin, photometric; reagents, potassium
cyanide and dimethyllaurylamine oxide
K3E K3EDTA
Eosinophilocytes
Haemoglobin
Large unstained cells
Leukocytes
Lymphocytes
Monocytes
Neutrophilocytes
Thrombocytes
∗Analytes reanalysed with serial dilutions of the contrast agent (concentrations of 6 and 3mg iodine/mL and 0.25 and 0.125mM gadolinium).
affected by the incubation time were the albumin, urea, crea-
tinine, ionized calcium, coagulation factors, and haematology
assays.
Some assays did not show a clinically relevant change at
the high dose but rather at 1/2 or 1/4 of this dose. Those
assays and their respective CAs are the following: bilirubin,
iodixanol (6mg iodine/mL) and iomeprol (6mg iodine/mL);
calcium, gadoxetate disodium (0.125mMGd); coagulation
factors, iomeprol (6mg iodine/mL); and magnesium, iodix-
anol (6mg iodine/mL). The assays that exhibited clinically
relevant changes at high and reduced concentrations were
serum calcium, iron, sodium, zinc, and magnesium and are
shown in Figure 1.
3.1. Colorimetric Calcium Assay. A positive interference was
observed with both ICAs in the colorimetric calcium assay
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Figure 1: Interferogram presenting iodixanol and iomeprol interference in calcium assays (a), gadoxetate disodium interference in the iron
(b) and zinc assays (c), and iomeprol interference in the magnesium assay (d). The error bars represent the SEM.∗𝑝 < 0.05 from Student’s
𝑡-test, ∗∗𝑝 < 0.01 from Student’s 𝑡-test, and ∗∗∗𝑝 < 0.001 from Student’s 𝑡-test.
using Arsenazo III dye (Figure 1(a)). This effect is concentra-
tion dependent for both agents, iodixanol (𝑝 = 0.0005) and
iomeprol (𝑝 = 0.003). The effect with iodixanol was signifi-
cantly different when compared with iomeprol (𝑝 = 0.0053),
according to the ANOVA test.
3.2. Colorimetric Iron Assay. A negative interference was
observed with gadoxetate disodium in the iron assay using
a 3-pyridine sulphonamide dye (Figure 1(b)).The figure indi-
cates an increase in the effect with increasing GdCA concen-
trations, but this is not statistically significant (𝑝 = 0.063),
according to the ANOVA test.
3.3. Colorimetric Zinc Assay. A negative interference was
observed with gadoxetate disodium in the zinc assay using
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a 5-Br-PAPS dye (Figure 1(c)). This effect is concentration
dependent (𝑝 < 0.0001), according to the ANOVA test.
3.4. Colorimetric Magnesium Assay. A negative interference
was observed with iomeprol in the magnesium assay using a
formazan dye derivative (Figure 1(d)).The effect is concentra-
tion dependent (𝑝 = 0.0056), according to the ANOVA test.
3.5. Potentiometric Sodium Assay. A negative interference
with both ICAs was observed in the sodium assay, which
is a direct (undiluted) potentiometric assay using methyl
monensin as an ionophore (Table 2). The effect is clinically
relevant at reduced concentrations and is concentration
dependent for iomeprol (𝑝 = 0.022).The effectwith iodixanol
was significantly different from that of iomeprol (𝑝 = 0.038),
according to the ANOVA test. Unfortunately, the results of
this assay are biased by the use of saline when correcting for
dilution.
No analytical interference was observed in any of the 29
assays with the two nonspecific extracellular GdCAs, gado-
butrol and gadoterate meglumine, and no clinically relevant
effects were observed with either CAs on the alanine amino
transferase, alkaline phosphatase, aspartate amino trans-
ferase, glucose, and urea assays using the Vitros 5.1 FS Chem-
istry System and the corresponding dry chemistry method.
Furthermore, the CAs did not induce analytical interference
in the C-reactive protein assay that was performed on the
KonelabTM PRIME 60i Clinical Chemistry Analyzer, or the
haematology assays performed on the ADVIA 2120i System.
4. Discussion
The main finding in this study is the extent of analytical
interference observed with ICAs, some of which were pre-
viously unreported. Interestingly, a larger effect is produced
by iodixanol than by iomeprol. The analytes at risk of
analytical interference by CAs are mainly endogenous ions.
The analytical interferences that were observed only at the
high concentrations, 12mg iodine/mL and 0.5mMGd, are
considered clinically relevant when performed shortly after
injections of CAs or for patients with impaired renal function.
The positive interference by nonionic ICAs in assays for
calcium has not been reported previously. In 1994, Hayakawa
et al. [27] reported a negative interference by ionic ICAs in the
determination of ionized calcium, and the effect was attrib-
uted to the unbound anions of the ionic ICAs and their poten-
tiation of calcium binding. This mechanism of action cannot
possibly explain the observed effect in our study, which is
a positive interference by nonionic ICAs. ICAs formulated
with calcium binding additives have been known to cause
spurious hypocalcemia from interference [37, 38]. The high
stability of iomeprol enables it to be formulated without a
calciumchelating agent, whereas iodixanol is formulatedwith
sodium calcium ethylenediaminetetraacetic acid (Na2-Ca-
EDTA), a chelate that does not bind additional calcium [27,
39, 40]. Iodixanol is formulated isotonically with blood by
the addition of sodium and calcium electrolytes, which may
explain the larger effect in the colorimetric assay compared
to iomeprol. A mechanism of action based on the interaction
between ICA and the chromophore may be proposed and
is justified by the lack of interference from iomeprol on the
ionized calcium assay. In vivo studies have not demonstrated
this effect by iodixanol in blood calciummeasurements, thus
indicating an artefactual in vitro effect [39, 41].
The lack of an effect of gadoxetate disodium, gadoterate
meglumine, and gadobutrol on the calcium assays is support-
ed by others, as analytical interference in calcium assays has
been attributed to the reduced complex stability and excess
ligand in the formulation of the nonionic linear GdCAs
[8, 9, 11, 15]. Evidence points to the fact that gadopentetate
dimeglumine, gadoterate, gadoteridol, gadobutrol, gadobe-
nate dimeglumine, and gadoxetate disodium do not cause
analytical interference in colorimetric calcium assays, regard-
less of which colorimetric technique was used [2, 6–9, 11–13].
Only nonionic linear GdCAs are relevant when considering
Gd chelate binding as a mechanism in the analytical interfer-
ence by CAs in laboratory blood tests [2–4, 6–8, 11–13, 15].
Analytical interference by GdCAs in iron assays has been
reported with different agents and in different assays, in
which the observed lack of analytical interference by macro-
cyclic agents on iron determination is supported by the liter-
ature [5, 12, 14, 15]. Recent reports have linked the observed
negative interference by linear GdCAs to dissociation of the
gadolinium complex, which is caused by transmetallation
between the ferric ion and gadolinium [15, 42], a mechanism
also attributed to the negative interference caused by GdCAs
in zinc assays [11, 16]. In this study, only the ionic linearGdCA,
gadoxetate disodium, exhibited analytical interference in the
zinc assay. Proctor et al. [12] reported analytical interference
in zinc assays by the nonionic macrocyclic GdCA, gadoteri-
dol, and by linear agents. No effect was observed in this study
with gadobutrol, which is also a nonionic macrocyclic agent.
Furthermore, GdCA injections have been linked to zincuria
[16], and future studies should focus on resolving whether it
is a “factual” in vivo or an “artefactual” in vitro effect.
Analytical interference in themagnesium assay was solely
exhibited by the ICA iomeprol, and this is an unreported
effect. The lack of interference by the GdCAs is supported by
others, as the analytical interference by GdCAs on the deter-
mination of magnesium has been credited to the nonionic
linear agents [12].
The lower sodium assay results may also be explained
by relatively more sodium in the control solution. Sodium
was present in both the CA and the physiological saline that
was added to adjust the volume. However, the various CA
may have less than physiological sodium concentrations.The
observed changes in sodium may, therefore, be true and not
due to analytical interference.
Studies indicate a lack of awareness in daily clinical
work regarding analytical interference by CAs [11, 13]. Spu-
rious results from laboratory assays may cause unnecessary
treatment, diagnostic confusion, unnecessary distress to the
patient, and increased use of healthcare resources [43]. For
these reasons,manufacturers of diagnostic tests should exam-
ine for CA interference and document their results.TheEuro-
pean Society of Urogenital Radiology Guidelines on Contrast
Media recommend that biochemical analyses are avoided on
blood and urine collected in the 24 hours after CA injection.
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Thepresent findings indicate that this recommendation could
be reduced to 4 hours, in which 75% of the injected CA has
been eliminated in patients with normal renal function [28].
However, it is preferable if the blood and/or urine samples are
collected before the CA is administered.
The limitations in this study were as follows: (1) no exper-
iments were performed to understand the underlying mech-
anism, thus making it difficult to distinguish “factual” in vivo
effects from “artefactual” in vitro effects. (2) Due to the vary-
ing workload of patient samples in the laboratory, the incuba-
tion time could vary between 2 and 4 h.The observed signifi-
cant effects from incubation time indicate that a reduction in
the variation of incubation timewould improve both the gen-
erated results and the reproducibility. (3) In addition to the
calcium assays, this study did not include multiple assays on
single analytes and precautions should be taken when com-
paring the results with those achieved by a different method.
(4) The current data do not disclose whether the change
in sodium was due to addition, dilution, interference, or a
combination thereof. Further experiments taking the sodium
concentration of CA into account are required to clarify this
question.
In conclusion, some CAs cause analytical interference.
Attention should be given to the analyte-CA combinations
listed in Table 2 when assessing laboratory blood test results
obtained after CA administration. Further research in vivo
on the mechanism of action is needed to distinguish between
factual and artefactual effects.
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